Porous chitosan-hyaluronic acid scaffolds as a mimic of glioblastoma microenvironment ECM

Biomaterials

Volumn 34, Issue 38, 2013, Pages 10143-10150

  Florczyk, Stephen J ^a   Wang, Kui ^a   Jana, Soumen ^a   Wood, David L ^a   Sytsma, Samara K ^a   Sham, Jonathan G ^b   Kievit, Forrest M ^a,b   Zhang, Miqin ^a,b  

^a University of Washington   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer stem cell; Glioma; Invasion; Multidrug resistance; Spheroid

Indexed keywords

CANCER STEM CELLS; GLIOMA; INVASION; MULTIDRUG RESISTANCE; SPHEROID;

CHEMOTHERAPY; CHITOSAN; COMPLEX NETWORKS; DIAGNOSIS; DISEASES; HYALURONIC ACID; ORGANIC ACIDS; STEM CELLS; THREE DIMENSIONAL; TUMORS; TWO DIMENSIONAL;

SCAFFOLDS (BIOLOGY);

BREAST CANCER RESISTANCE PROTEIN; CD44V ANTIGEN; CHITOSAN; DOXORUBICIN; GLIAL FIBRILLARY ACIDIC PROTEIN; HYALURONIC ACID; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MUSASHI 1; NESTIN; PROTEIN; RNA BINDING PROTEIN; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ARTICLE; CANCER RESISTANCE; CANCER STEM CELL; CARCINOGENESIS; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; EXTRACELLULAR MATRIX; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR MICROENVIRONMENT; UPREGULATION; YOUNG MODULUS;

CANCER STEM CELL; GLIOMA; INVASION; MULTIDRUG RESISTANCE; SPHEROID;

CELL LINE, TUMOR; CELL PROLIFERATION; CHITOSAN; EXTRACELLULAR MATRIX; GLIOBLASTOMA; HUMANS; HYALURONIC ACID; MICROSCOPY, ELECTRON, SCANNING; POROSITY; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; TISSUE SCAFFOLDS;

EID: 84885372193     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.09.034     Document Type: Article

References (66)

1. Louis D., Ohgaki H., Wiestler O., Cavenee W., Burger P., Jouvet A., et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007, 114:97-109.
2. Holland E.C. Glioblastoma multiforme: the terminator. Proc Natl Acad Sci U S A 2000, 97:6242-6244.
3. Stupp R., Mason W.P., van den Bent M.J., Weller M., Fisher B., Taphorn M.J.B., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. NEngl J Med 2005, 352:987-996.
4. Bissell M.J., Hines W.C. Why don't we get more cancer? a proposed role of the microenvironment in restraining cancer progression. Nat Med 2011, 17:320-329.
5. Hutmacher D.W. Biomaterials offer cancer research the third dimension. Nat Mater 2010, 9:90-93.
6. Hutmacher D.W., Loessner D., Rizzi S., Kaplan D.L., Mooney D.J., Clements J.A. Can tissue engineering concepts advance tumor biology research?. Trends Biotechnol 2010, 28:125-133.
7. Kimlin L.C., Casagrande G., Virador V.M. Invitro three-dimensional (3D) models in cancer research: an update. Mol Carcinog 2013, 52:167-182.
8. Benton G., George J., Kleinman H.K., Arnaoutova I.P. Advancing science and technology via 3D culture on basement membrane matrix. JCell Physiol 2009, 221:18-25.
9. Benton G., Kleinman H.K., George J., Arnaoutova I. Multiple uses of basement membrane-like matrix (BME/Matrigel) invitro and invivo with cancer cells. Int J Cancer 2011, 128:1751-1757.
10. Feder-Mengus C., Ghosh S., Reschner A., Martin I., Spagnoli G.C. New dimensions in tumor immunology: what does 3D culture reveal?. Trends Mol Med 2008, 14:333-340.
11. Fischbach C., Chen R., Matsumoto T., Schmelzle T., Brugge J.S., Polverini P.J., et al. Engineering tumors with 3D scaffolds. Nat Methods 2007, 4:855-860.
12. Fischbach C., Kong H.J., Hsiong S.X., Evangelista M.B., Yuen W., Mooney D.J. Cancer cell angiogenic capability is regulated by 3D culture and integrin engagement. Proc Natl Acad Sci U S A 2009, 106:399-404.
13. Hirschhaeuser F., Menne H., Dittfeld C., West J., Mueller-Klieser W., Kunz-Schughart L.A. Multicellular tumor spheroids: an underestimated tool is catching up again. JBiotechnol 2010, 148:3-15.
14. Kievit F.M., Florczyk S.J., Veiseh O., Park J.O., Disis M.L., Zhang M. Chitosan-alginate 3D scaffolds as a mimic of the glioma tumor microenvironment. Biomaterials 2010, 31:5903-5910.
15. Kleinman H.K., Martin G.R. Matrigel: basement membrane matrix with biological activity. Semin Cancer Biol 2005, 15:378-386.
16. Scott J.E. Supramolecular organization of extracellular matrix glycosaminoglycans, invitro and in the tissues. FASEB J 1992, 6:2639-2645.
17. Toole B.P. Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer 2004, 4:528-539.
18. Rinaudo M. Main properties and current applications of some polysaccharides as biomaterials. Polym Int 2008, 57:397-430.
19. Muzzarelli R.A.A. Chitosan composites with inorganics, morphogenetic proteins and stem cells, for bone regeneration. Carbohydr Polym 2011, 83:1433-1445.
20. Schanté C.E., Zuber G., Herlin C., Vandamme T.F. Chemical modifications of hyaluronic acid for the synthesis of derivatives for a broad range of biomedical applications. Carbohydr Polym 2011, 85:469-489.
21. Sironen R.K., Tammi M., Tammi R., Auvinen P.K., Anttila M., Kosma V.-M. Hyaluronan in human malignancies. Exp Cell Res 2011, 317:383-391.
22. Toole B.P. Hyaluronan-CD44 interactions in cancer: paradoxes and possibilities. Clin Cancer Res 2009, 15:7462-7468.
23. Veiseh M., Turley E.A. Hyaluronan metabolism in remodeling extracellular matrix: probes for imaging and therapy of breast cancer. Integr Biol 2011, 3:304-315.
24. Naor D., Wallach-Dayan S.B., Zahalka M.A., Sionov R.V. Involvement of CD44, a molecule with a thousand faces, in cancer dissemination. Semin Cancer Biol 2008, 18:260-267.
25. Wang X.M., He J., Wang Y., Cui F.Z. Hyaluronic acid-based scaffold for central neural tissue engineering. Interface Focus 2012, 2:278-291.
26. Berger J., Reist M., Mayer J.M., Felt O., Gurny R. Structure and interactions in chitosan hydrogels formed by complexation or aggregation for biomedical applications. Eur J Pharm Biopharm 2004, 57:35-52.
27. Rinaudo M. Properties and degradation of selected polysaccharides: hyaluronan and chitosan. Corros Eng Sci Technol 2007, 42:324-334.
28. Tan H., Chu C.R., Payne K.A., Marra K.G. Injectable in situ forming biodegradable chitosan-hyaluronic acid based hydrogels for cartilage tissue engineering. Biomaterials 2009, 30:2499-2506.
29. Tan H., Rubin J.P., Marra K.G. Injectable in situ forming biodegradable chitosan-hyaluronic acid based hydrogels for adipose tissue regeneration. Organogenesis 2010, 6:173-180.
30. Coimbra P., Alves P., Valente T.A.M., Santos R., Correia I.J., Ferreira P. Sodium hyaluronate/chitosan polyelectrolyte complex scaffolds for dental pulp regeneration: synthesis and characterization. Int J Biol Macromol 2011, 49:573-579.
31. Correia C.R., Moreira-Teixeira L.S., Moroni L., Reis R.L., van Blitterswijk C.A., Karperien M., et al. Chitosan scaffolds containing hyaluronic acid for cartilage tissue engineering. Tissue Eng Part C Methods 2011, 17:717-730.
32. Campbell J.J., Davidenko N., Caffarel M.M., Cameron R.E., Watson C.J. Amultifunctional 3D co-culture system for studies of mammary tissue morphogenesis and stem cell biology. PLoS One 2011, 6:e25661.
33. Leung M., Kievit F.M., Florczyk S.J., Veiseh O., Wu J., Park J.O., et al. Chitosan-alginate scaffold culture system for hepatocellular carcinoma increases malignancy and drug resistance. Pharm Res 2010, 27:1939-1948.
34. Florczyk S.J., Liu G., Kievit F.M., Lewis A.M., Wu J.D., Zhang M. 3D porous chitosan-alginate scaffolds: a new matrix for studying prostate cancer cell-lymphocyte interactions invitro. Adv Healthc Mater 2012, 1:590-599.
35. Edmondson D., Bhattarai N., Jana S., Kim A., Zhang M. Design and evaluation of a nano-scale differential tensile test device for nanofibers. Appl Phys Lett 2009, 94:103101.
36. Miller A.M., Stella N. Microglial cell migration stimulated by ATP and C5a involve distinct molecular mechanisms: quantification of migration by a novel near-infrared method. Glia 2009, 57:875-883.
37. Pettikiriarachchi J.T.S., Parish C.L., Shoichet M.S., Forsythe J.S., Nisbet D.R. Biomaterials for brain tissue engineering. Aust J Chem 2010, 63:1143-1154.
38. Gilbert P.M., Havenstrite K.L., Magnusson K.E.G., Sacco A., Leonardi N.A., Kraft P., et al. Substrate elasticity regulates skeletal muscle stem cell self-renewal in culture. Science 2010, 329:1078-1081.
39. Ananthanarayanan B., Kim Y., Kumar S. Elucidating the mechanobiology of malignant brain tumors using a brain matrix-mimetic hyaluronic acid hydrogel platform. Biomaterials 2011, 32:7913-7923.
40. Merzak A., Koocheckpour S., Pilkington G.J. CD44 mediates human glioma cell adhesion and invasion invitro. Cancer Res 1994, 54:3988-3992.
41. Anido J., Saez-Borderias A., Gonzalez-Junca A., Rodon L., Folch G., Carmona M.A., et al. TGF-beta receptor inhibitors target the CD44(high)/Id1(high) glioma-initiating cell population in human glioblastoma. Cancer Cell 2010, 18:655-668.
42. Stiles C.D., Rowitch D.H. Glioma stem cells: a midterm exam. Neuron 2008, 58:832-846.
43. Reynolds B.A., Weiss S. Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system. Science 1992, 255:1707-1710.
44. Salmaggi A., Boiardi A., Gelati M., Russo A., Calatozzolo C., Ciusani E., et al. Glioblastoma-derived tumorospheres identify a population of tumor stem-like cells with angiogenic potential and enhanced multidrug resistance phenotype. Glia 2006, 54:850-860.
45. Strojnik T., Rosland G.V., Sakariassen P.O., Kavalar R., Lah T. Neural stem cell markers, nestin and musashi proteins, in the progression of human glioma: correlation of nestin with prognosis of patient survival. Surg Neurol 2007, 68:133-144.
46. Wan F., Herold-Mende C., Campos B., Centner F.-S., Dictus C., Becker N., et al. Association of stem cell-related markers and survival in astrocytic gliomas. Biomarkers 2011, 16:136-143.
47. Okano H., Imai T., Okabe M. Musashi: a translational regulator of cell fate. JCell Sci 2002, 115:1355-1359.
48. Toda M., Iizuka Y., Yu W., Imai T., Ikeda E., Yoshida K., et al. Expression of the neural RNA-binding protein musashi1 in human gliomas. Glia 2001, 34:1-7.
49. Gürsel D.B., Shin B.J., Burkhardt J.-K., Kesavabhotla K., Schlaff C.D., Boockvar J.A. Glioblastoma stem-like cells-biology and therapeutic implications. Cancers 2011, 3:2655-2666.
50. Zhang Q.B., Ji X.Y., Huang Q., Dong J., De Zhu Y., Lan Q. Differentiation profile of brain tumor stem cells: a comparative study with neural stem cells. Cell Res 2006, 16:909-915.
51. Kaur B., Khwaja F.W., Severson E.A., Matheny S.L., Brat D.J., Van Meir E.G. Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. Neuro Oncol 2005, 7:134-153.
52. Bar E.E. Glioblastoma, cancer stem cells and hypoxia. Brain Pathol 2011, 21:119-129.
53. Zagzag D., Zhong H., Scalzitti J.M., Laughner E., Simons J.W., Semenza G.L. Expression of hypoxia-inducible factor 1 alpha in brain tumors - association with angiogenesis, invasion, and progression. Cancer 2000, 88:2606-2618.
54. Li Z., Bao S., Wu Q., Wang H., Eyler C., Sathornsumetee S., et al. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell 2009, 15:501-513.
55. Soeda A., Park M., Lee D., Mintz A., Androutsellis-Theotokis A., McKay R.D., et al. Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1 alpha. Oncogene 2009, 28:3949-3959.
56. Kim J.W., Ho W.J., Wu B.M. The role of the 3D environment in hypoxia-induced drug and apoptosis resistance. Anticancer Res 2011, 31:3237-3245.
57. Bar E.E., Lin A., Mahairaki V., Matsui W., Eberhart C.G. Hypoxia increases the expression of stem-cell markers and promotes clonogenicity in glioblastoma neurospheres. Am J Pathol 2010, 177:1491-1502.
58. Lakka S.S., Rajan M., Gondi C., Yanamandra N., Chandrasekar N., Jasti S.L., et al. Adenovirus-mediated expression of antisense MMP-9 in glioma cells inhibits tumor growth and invasion. Oncogene 2002, 21:8011-8019.
59. Deryugina E.I., Bourdon M.A., Luo G.X., Reisfeld R.A., Strongin A. Matrix metalloproteinase-2 activation modulates glioma cell migration. JCell Sci 1997, 110:2473-2482.
60. Mikheeva S.A., Mikheev A.M., Petit A., Beyer R., Oxford R.G., Khorasani L., et al. TWIST1 promotes invasion through mesenchymal change in human glioblastoma. Mol Cancer 2010, 9.
61. Elias M.C., Tozer K.R., Silber J.R., Mikheeva S., Deng M., Morrison R.S., et al. TWIST is expressed in human gliomas and promotes invasion. Neoplasia 2005, 7:824-837.
62. Pistollato F., Abbadi S., Rampazzo E., Persano L., Della Puppa A., Frasson C., et al. Intratumoral hypoxic gradient drives stem cells distribution and MGMT expression in glioblastoma. Stem Cells 2010, 28:851-862.
63. Bleau A.-M., Huse J.T., Holland E.C. The ABCG2 resistance network of glioblastoma. Cell Cycle 2009, 8:2937-2945.
64. Martin V., Sanchez-Sanchez A.M., Herrera F., Gomez-Manzano C., Fueyo J., Alvarez-Vega M.A., et al. Melatonin-induced methylation of the ABCG2/BCRP promoter as a novel mechanism to overcome multidrug resistance in brain tumour stem cells. Br J Cancer 2013, 108:2005-2012.
65. Chua C., Zaiden N., Chong K.-H., See S.-J., Wong M.-C., Ang B.-T., et al. Characterization of a side population of astrocytoma cells in response to temozolomide. JNeurosurg 2008, 109:856-866.
66. Dean M., Fojo T., Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005, 5:275-284.